BD Phoenix™ M50 Automated ID/AST Solution
Put your lab at the forefront in the fight against antimicrobial resistance and protect the last line of defense.
- Overview
- Applications
- Product Videos
- Products & Accessories
- EIFU & Resources
We are facing a growing crisis; antimicrobial resistance is eroding our last line of defense against life-threatening infections.
In the U.S., up to 56% of antimicrobial therapies are used inappropriately.1 That’s more than half—driven by overprescription, incorrect dosing, and lack of diagnostic clarity. Not only does inappropriate therapy put the patient at risk, but it also drives resistance. Patients with multidrug-resistant infections face 84% higher odds of dying compared to those with treatable infections.2 This isn’t just a statistic—it’s a life-or-death reality for thousands. And the financial impact is staggering. MDR infections can cost hospitals up to $30,000 per patient,3 straining already limited resources and increasing the burden on care teams.
The BD Phoenix™ M50 helps clinical laboratories to strengthen their defense against antimicrobial resistance. The BD Phoenix™ allows laboratories to treat with confidence with ~50% lower very major errors1 and provide less intensity with more impact with up to 71% less offline testing than bioMérieux Vitek®.2 It also provides dynamic intelligence with BD Synapsys™ to strengthen stewardship and track resistance.
Put your lab at the forefront in the fight against antimicrobial resistance and protect the last line of defense with BD Phoenix™ M50.
Treat with Confidence
BD Phoenix™ M50 Automated ID/AST Solution delivers highly accurate results and the most complete picture of microbial activity while avoiding downstream workflow inefficiencies.
- Demonstrates ~ 50% lower rate of VMEs (Very Major Errors) for Gram-negative organisms compared to bioMerieux Vitek®4
- True MIC results achieved from dilutions using doubling antibiotic concentrations, and the reading of every well, no extrapolated results
- 136 panel well design accommodates all clinically relevant antimicrobials, reducing the need for offline testing
- In an average lab, BD Phoenix™ usage would result in up to 71% less offline testing annually (compared to bioMerieux Vitek®)5*
- Advanced detection algorithms detect what others might miss
Every well counts and every well contributes to higher accuracy
BD Phoenix™ panels support true MICs and complete breakpoint coverage, ensuring clinicians get the most accurate data from every test.
- 136-well design provides the highest analytical throughput per panel enabling true doubling dilutions and precise MIC determination
- Optimized well layout accommodates all clinically relevant antimicrobials reducing the need for offline testing
- Ensures critical concentrations are included to detect resistance at or near clinical breakpoints
- Layout allows for updates as resistance patterns and guidelines evolve
Learn more about the BD Phoenix™ panels.
Modular and ease-of-use design to strengthen your defense against AMR
- Compact stackable design (up to two instruments)
- Double capacity with same footprint
- No reagent additions post inoculation
The BD Phoenix™ automated inoculum preparation instrument can be combined with BD Phoenix™ M50 System to help reduce sample preparation workflow burden.6,7
Protect today’s patients and tomorrow’s populations
Add dynamic intelligence to your diagnostics with BD Synapsys™ informatics connectivity to BD Phoenix™ and advance your antimicrobial stewardship efforts
Cascading antimicrobial reporting (CAR)*
- Prioritize antibiotics for bug/drug susceptibility
- Strengthen stewardship by tracking resistance trends
Data-driven insights
- Antibiograms, organism and resistance markers
- Enhance stewardship through narrow-spectrum antibiotic usage
*CAR – patent pending
Strengthen your defense
The BD Bloodstream Infection Solution with BD Phoenix and the dynamic intelligence of BD Synapsys is helping microbiology labs to strengthen your defense against antimicrobial resistance.
Bloodstream Infection Solution
BD Clinical and Lab Support
BD Diagnostic Solutions is Now Waters Advanced Diagnostics
BD Diagnostic Solutions and Biosciences have combined with Waters Corporation to create a life sciences and diagnostics leader driven by innovation and a relentless commitment to our customers.
As we begin our new journey as part of Waters, there will be no immediate changes in how we serve you. The way you order your products and services and how you process payment for them will not change. Your points of contact for sales, customer service, technical service and support or clinical services will remain the same.
- The BD Phoenix™ M50 system instrument offers identification-only panels and combination ID/AST panels, using 51 wells for identification substrates.
- The system can provide rapid identification of most clinically significant Gram-negative and Gram- positive bacteria, as well as yeast.
- The BD Phoenix™ M50 system offers 85 wells for antimicrobial dilutions on standard AST-only panels and combination ID/AST panels, and 136 wells on the BD Phoenix™ Emerge™ panel.
- The instrument can provide rapid susceptibility results for most clinically significant Gram-negative and Gram-positive bacteria.
- The BD Phoenix™ M50 system panels test for several resistance markers*such as**:
- Gram-positive bacteria
- HLAR—High Level Aminoglycoside Resistant Enterococcus
- iMLSb—Inducible Clindamycin Resistance
- MRSA—based on Oxacillin Interpretation with Staphylococcus species
- mecA – detection of mecA-medicated resistance in Staphylococcus aureus
- BL- Staphylococcus ß-Lactamase (Nitrocefin based test)
- VRSA—Vancomycin-Resistant Staphylococcus Aureus
- VRE—based on Vancomycin interpretation
- Gram-negative bacteria
- CPO—Carbapenemase Producing Organism
- ESBL—offered on Gram-negative panels and requires no additional disc diffusion or E-Test confirmation.
- Gram-positive bacteria
* Depending on BD Phoenix™ panel type and organism identification
- The BD Phoenix™ CPO detect test, available on certain BD Phoenix™ Gram-negative panels, provides information, including Ambler classification, to help guide clinicians in their treatment decisions.
- This test is available in two-panel configurations that allow microbiology labs to test for CPOs as part of routine susceptibility testing on BD Phoenix™ panels:
- 2-well configuration—provides detection of Carbapenemase-producing organisms in Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii
- 9-well configuration—provides detection of carbapenemase-producing organisms and Ambler classification (A, B or D) in Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii
- The BD Phoenix™ CPO detect test is currently the only phenotypic test on an automated AST system that provides CPO detection and Ambler classification.
- On average, the BD Phoenix™ CPO detect test detects and classifies CPOs from isolated colonies within 6 to 11 hours.**
**BD internal studies—data on file
BD Phoenix™ M50 Automated ID/AST
System delayed growth algorithm.
BD Phoenix™ M50 Automated ID/AST
System flexible panel format
BD Phoenix™ M50 Automated ID/AST
System dual growth detection
Our collection of literature on industries and on our offerings gives you information you can use to continue striving for excellence.
We support the healthcare industry with market-leading products and services that aim to improve care while lowering costs. We host and take part in events that excel in advancing the world of health™.
The BD Learning Academy offers a centralized repository of BD product training, education, and the ability to connect courses to your LMS.
We promote clinical excellence by providing various resources on best practices, clinical innovations and industry trends in healthcare.
- Magill SS, O’Leary E, Ray SM, et al. Assessment of the Appropriateness of Antimicrobial Use in US Hospitals. JAMA Netw Open. 2021;4(3):e212007. doi:10.1001/jamanetworkopen.2021.2007
- Poudel AN, Zhu S, Cooper N, Little P, Tarrant C, Hickman M, Yao G. The economic burden of antibiotic resistance: A systematic review and meta-analysis. PLoS One. 2023 May 8;18(5):e0285170. doi: 10.1371/journal.pone.0285170. PMID: 37155660; PMCID: PMC10166566.
- Juang P, Lindsey P, Micek ST, Kollef MH. Cost Implication of Inappropriate Empiric Antibiotics in Gram-Negative Infections. Hosp Pharm. 2024 Dec 12:00185787241303035. doi: 10.1177/00185787241303035. Epub ahead of print. PMID: 39677556; PMCID: PMC11635783
- Van Benten, K., Cooper, L., Parvu, V., Gary, D., Kruer, S., & Kodsi, S. (2025, June). Agreement and error rates in antimicrobial susceptibility testing for three commercial, automated systems: A meta-analysis [Poster presentation]. ASM Microbe, Los Angeles, CA. Poster P2056.
- Based on BD ID/AST TCO Model. Example for demonstration purposes of average size US laboratory and average positivity rates. Model backed by data gathered from US hospital laboratories from BD Insights Research Database (Becton, Dickinson and Company, Franklin Lakes, NJ)
- Junkins A et al. J. Clin. Microbiol. 2010;48(5):1929–31.
- Jungkind D et al. Workflow evaluation of the BD Phoenix™ AP Compared to the MicroScan Walkaway overnight system for identification and susceptibility testing of bacteria. Poster presented at the 110th General Meeting of the American Society of Microbiology. May 2010. Study was supported by grants from BD Diagnostic Systems.
*Based on lab performing 400,000 tests per year with an average positivity rate of 8.2% reporting on common clinically relevant antimicrobials.
Disclaimer:
This business has been acquired by Waters Corporation (“Waters”). For products referenced on this page, the legal manufacturer remains Becton, Dickinson and Company or one of its affiliates or subsidiaries (“BD”) until all required regulatory transfers are completed. During this interim period, BD maintains full responsibility for all regulatory obligations of the legal manufacturer. Product information provided here is supplied under the regulatory authority of BD. To learn more about the relationship between Waters and BD during this transition period, please see our detailed summary waters.com/bdtransaction.